The rise in the global female prison population, women’s unique vulnerabilities to HIV infection and insufficient provision and inequitable access to HIV services places the prevention of mother-to-child transmission (PMTCT) in prisons high on the agenda of HIV prevention among key populations.
Women
Resource
May 18, 2020
Resource
May 13, 2020
This publication marks the 25th anniversary of the Beijing Declaration and Platform for Action.
Resource
May 4, 2020
This study has two phases. It will be conducted in one site in CT only. Phase I is to enumerate interest in PrEP uptake among young South African women exposed to a culturally-appropriate social marketing campaign.
Resource
May 4, 2020
Status
Ongoing
Phase
Demo Project
Objective
News
April 15, 2020
According to the Commission for Gender Equality’s latest report on forced and coerced sterilisations in South Africa, the practice is a direct attack on HIV-positive women’s constitutionally enshrined rights, and highlights flaws in public health’s informed consent procedures.
Resource
December 30, 2019
We examine acceptability of a long‐acting injectable PrEP among HIV‐uninfected women in Zimbabwe, South Africa and two United States phase 2 trial sites.
Resource
December 14, 2019
A training curriculum published by WHO to provide healthcare providers with the knowledge and skills that they need to know how to best help women who are living with violence.
Resource
October 10, 2019
Women account for 56% of new HIV infections in sub-Saharan Africa. Multipurpose Prevention Technologies (MPTs) are promising interventions because they combine HIV prevention with a less stigmatizing indication, such as pregnancy. We conducted a study with three placebo-only MPT products in Kisumu, Kenya and Soshanguve, South Africa, to assess preferences for attributes of tablets, vaginal rings and injectable products for dual prevention of HIV and pregnancy (TRIO Study). Here, we present former TRIO participants' views on the study results.
Resource
September 2, 2019
The World Health Organization (WHO) convened a Guideline Development Group (GDG) meeting from 29 to 31 July 2019 to review global guidance on contraceptive eligibility for women at high risk of HIV acquisition to and determine whether revisions to the fifth edition of the Medical eligibility crit
News
September 2, 2019
Women at high risk for HIV infection can use any form of reversible hormonal contraception without any restrictions, including progestogen-only injectables, implants, and intrauterine devices (IUDs), the World Health Organization (WHO) said.
